Renin and Aldosterone Levels in the Preterm Neonate At Risk for Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

76 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if mothers with high blood pressure (Hypertension) and/or diabetes have babies with high levels of different substances (that help to regulate blood pressure, called Renin and Aldosterone) in their blood. The investigators are also trying to determine if these babies have higher blood pressure than those babies born to mothers without high blood pressure or diabetes, during the first year of life.

The investigators will measure your baby's blood pressure once a day for the first 4 days, at 1 week of age, and then once per week until your baby is discharged. The investigators will also measure the blood pressure after discharge at 4 and 10 months of age, either on the day of your baby's follow-up appointment in the Neonatal Follow-up Clinic or at a visit to our Outpatient Nephrology Clinic, both at CHEO.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Renin and Prorenin in Pregnancy

NCT00005207

Cardiovascular Diseases Heart Diseases Hypertension +2 more

COMPLETED

HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)

NCT05636995

Primary Hyperaldosteronism Hypertensive Disorder of Pregnancy

ACTIVE_NOT_RECRUITING

First-trimester Prediction of Preeclampsia

NCT02189148

Preeclampsia Severe Preeclampsia Fetal Growth Restriction +1 more

COMPLETED

Determining the Risk Elevation After Maternity

NCT02305745

Preeclampsia

UNKNOWN

Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn

NCT01648855

Preterm Birth Intra-uterine Growth Restriction Maternal Preeclampsia +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We will compare two groups of babies born between 26+0 and 34+0 weeks gestation.Group 1 is the babies born to mothers with diabetes and/or high blood pressure, and babies that are small for dates. Group 2 are babies that are 26 to 34 weeks of age, that are born to mothers without these problems.

In the study we will measure the baby's blood pressure once a day for the first 4 days, at 1 week of age, and then once per week until the baby is discharged. We will also measure the blood pressure after discharge at 4 and 10 months of age, either on the day of your baby's follow-up appointment in the Neonatal Follow-up Clinic or at a visit to our Outpatient Nephrology Clinic, both at CHEO.

As blood tests will be done. A small amount of extra blood, 0.75ml - 1.5 ml (about 1/6 -1/3 of a teaspoon, or approximately 1 ml) will be collected for measurement of the blood substances we are studying will be collected when the baby has their regular non-study blood work.

This will be done within six hours of birth and then again at 2-3 weeks of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Diabetes Infants Small for Gestational Age

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Babies of mothers that have diabetes and/or hypertension and babies that are small for dates

presence of maternal risk factor for hypertension

Intervention Type OTHER

Group 2

Babies born to mothers without diabetes and/or hypertension and babies that are correct size for gestational age

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

presence of maternal risk factor for hypertension

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Infants \< 6 hours of age who require NICU admission
2. Infants 26+0 to 34+0 weeks gestation.

Exclusion Criteria

* Immediate Exclusion from Enrollment

1. Maternal treatment with drugs known to be teratogenic and cause nephrotoxicity in the fetus (i.e. ACE-Inhibitor).
2. Infants with known congenital anomalies and/or renal anomalies.
3. Infants with known chromosomal anomalies.
4. Infants with severe asphyxia defined as cord pH \< 7.0, 5 min Apgar \< 3, and urine positive for blood.
5. Infants with a known or suspected blood loss at birth (ie: uterine rupture, placental abruption, bleeding placenta previa, or post-natal blood loss in the delivery room).
6. Infants who will not receive follow-up care in Ottawa upon discharge from the NICU (ie: live out of town).

Minimum Eligible Age

26 Weeks

Maximum Eligible Age

34 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No